Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
Phase of Trial: Phase II
Latest Information Update: 30 May 2016
At a glance
- Drugs Q 301 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Qurient Co
- 18 May 2016 Status changed from active, no longer recruiting to completed.
- 08 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 20 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.